Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized-Controlled Trial of AST-OPC1 in Patients with Spinal Cord Injuries

Trial Profile

A Phase II, Randomized-Controlled Trial of AST-OPC1 in Patients with Spinal Cord Injuries

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Therapeutic Use
  • Sponsors Asterias Biotherapeutics; Lineage Cell Therapeutics
  • Most Recent Events

    • 04 Sep 2019 According to an Lineage Cell Therapeutics media release, this study is expected to begin later in 2020.
    • 31 Jul 2019 According to an BioTime media release, the company has changed its name to Lineage Cell Therapeutics, Inc.
    • 24 Jan 2019 According to an Asterias Biotherapeutics media release, the Company held a Type B meeting with the Food and Drug Administration (FDA) late last year where FDA agreed with the companys plan to initiate this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top